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Abstract
Background: Epidemiologic studies suggest that maternal organophosphorus (OP) pesticide exposure is associated with
poorer fetal growth, but findings are inconsistent. We explored whether paraoxonase (PON1), a key enzyme involved in
detoxification of OPs, could be an effect modifier in this association.
Methods: The study population included 470 pregnant women enrolled in the CHAMACOS Study, a longitudinal cohort
study of mothers and children living in an agricultural region of California. We analyzed urine samples collected from
mothers twice during pregnancy for dialkyl phosphate (DAP) metabolites of OP pesticides. We analyzed maternal and fetal
(cord) blood samples for PON1 genotype (PON1192 and PON12108) and enzyme activity (paraoxonase and arylesterase).
Infant birth weight, head circumference, and gestational age were obtained from medical records.
Results: Infants’ PON1 genotype and activity were associated with birth outcome, but mothers’ were not. Infants with the
susceptible PON12108TT genotype had shorter gestational age (b=20.5 weeks, 95% Confidence Interval (CI): 20.9, 0.0) and
smaller head circumference (b=20.4 cm, 95% CI: 20.7, 0.0) than those with the PON12108CC genotype. Infants’ arylesterase
and paraoxonase activity were positively associated with gestational age. There was some evidence of effect modification
with DAPs: maternal DAP concentrations were associated with shorter gestational age only among infants of the susceptible
PON12108TT genotype (p-valueinteraction=0.09). However, maternal DAP concentrations were associated with larger birth
weight (p-valueinteraction=0.06) and head circumference (p-valueinteraction,0.01) in infants with non-susceptible genotypes.
Conclusions: Infants whose PON1 genotype and enzyme activity levels suggested that they might be more susceptible to
the effects of OP pesticide exposure had decreased fetal growth and length of gestation. PON1 may be another factor
contributing to preterm or low birth weight birth.
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Introduction
Organophosphorus (OP) pesticides are a class of widely used,
neurotoxic insecticides that include compounds such as chlorpyr-
ifos, diazinon, and malathion. Chlorpyrifos and diazinon were
used in household pest control products until 2000–2001, when
they were voluntarily phased out by the manufacturers. However,
use of these and other OP pesticides in agriculture continues, with
approximately 73 million pounds applied in the United States
each year [1]. Animal studies have found that prenatal exposure to
various OP pesticides is associated with poorer fetal growth in
rodents [2,3,4,5,6,7,8]. However, epidemiologic studies in humans
have shown less consistency.
Whyatt et al. [9] found that concentrations of chlorpyrifos in
umbilical cord blood were negatively associated with birth weight
and length among infants born to low-income minority mothers in
New York City before the year 2001. A recent small study of
mothers and newborns in New Jersey found no association of
chlorpyrifos in maternal or umbilical cord serum with any measure
of fetal growth [10]; however, the second study was conducted after
the residential phase-out and levels of chlorpyrifos exposure were
considerably lower. A separate study carried out in New York City
before the residential phase-out found no association of dialkyl
phosphate (DAP) OP pesticide metabolites in maternal urine with
birth weight or length, but did find a statistically significant inverse
association with head circumference [11]. In a study of low-income
women living in an agricultural community, we previously reported
no association of maternal urinary DAP metabolites with decreased
birth weight, length, or head circumference, but did find an
association with shorter length of gestation [12].
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epidemiologic studies is individual and population-level differences
in susceptibility to OPs [13,14]. Paraoxonase 1 (PON1) is a high-
density lipoprotein-associated enzyme whose primary physiologi-
cal function appears to be related to metabolism of oxidized lipids
[15,16] and innate immunity [17], but which also plays a critical
role in the metabolism and detoxification of OP pesticides.
Animals with low PON1 activity are more sensitive to the toxic
effects of some Ops, and treatment with exogenous PON1 can
reduce an animal’s response to the activated, oxon forms of OPs
[18]. PON1’s in vitro esterase activity can be measured against
several substrates including paraoxon, chlorpyrifos-oxon, dia-
zoxon, and phenyl acetate [19,20].
There is a wide variability in PON1 enzyme activity in humans
[21], which is influenced by several common single nucleotide
polymorphisms (SNPs) in the PON1 gene [22]. Of these, the most
functionally important SNPs appear to be at position 192 in the
coding region and 2108 in the promoter region [23]. The
PON1192 SNP results in a Q/R amino acid substitution that affects
the enzyme’s catalytic efficiency, with the R alloform hydrolyzing
chlorpyrifos-oxon more efficiently than the Q. In contrast, a T/C
allelic substitution at position 2108 in the promoter region
impacts the amount of enzyme expressed, with the PON12108CC
genotype displaying significantly higher levels of plasma PON1
[24].
Few studies have examined the interaction of PON1 enzyme
activity or genotype and OP pesticide exposure on birth outcome.
In the same New York City population described above [11],
Berkowitz et al. [25] found that urinary metabolites of chlorpyrifos
were not associated with fetal growth on their own, but found
significantly reduced head circumference in infants of mothers
with both detectable levels of urinary metabolites of chlorpyrifos
and low PON1 activity. Wolff et al. [11] also found statistically
significant interaction between maternal PON1 genotype/activity
and OP exposure for birth weight and length: maternal DAP
metabolites were inversely associated with birth weight, but only
among mothers with the more susceptible PON1192 QQ genotype,
and inversely associated with birth length, but only among
mothers with low paraoxonase activity [11]. Moreno-Banda et al.
[26] examined the odds of low birth weight and found significant
interaction between PON1192 genotype and work in greenhouses
among floriculture workers in Mexico; however, in this case,
greenhouse work was associated with non-significantly increased
odds of low birth weight among mothers with the PON1192 RR
genotype.
The present study expands upon our previous analysis of
maternal DAP metabolites and birth outcome, first by examining
the main effect of PON1 on fetal growth and length of gestation
and then by exploring interaction of maternal DAP levels and
PON1.
Methods
Study participants
Participants were pregnant women enrolled in the Center for
the Health Assessment of Mothers and Children of Salinas
(CHAMACOS), a longitudinal cohort study investigating the
effects of exposure to OP pesticides and other environmental
chemicals on the health of pregnant women and their children
[12]. The study population was comprised of low-income women
living in the Salinas Valley, an agricultural region of northern
California. Eligible women were at least 18 years of age, spoke
English or Spanish, qualified for government-sponsored low-
income health insurance (Medicaid), were less than 20 weeks
gestation, and were receiving prenatal care at one of six clinics that
served the farmworker community.
A total of 601 pregnant women were enrolled in the study and
538 were followed through delivery. We excluded stillbirths (n=3),
twins (n=5), infants weighing ,500 g at birth (n=1), women with
hypertension during pregnancy (n=15), and women with existing
or gestational diabetes (n=26). We also excluded mother-infant
pairs for whom we had no information on PON1 genotype or
activity (n=21), leaving a final sample size of 467. Of these, PON1
genotype information was available for 451 mothers and 436
infants, and PON1 activity data were available for 371 mothers
and 324 infants.
Ethics Statement
We obtained signed informed consent from all women at the
time of enrollment in the study. All study procedures were
approved by the Committee for the Protection of Human Subjects
at the University of California, Berkeley.
Data Collection
Women were interviewed at the end of the first (mean 6
standard deviation (SD)=13.666.5 weeks) and second (mean 6
SD=25.862.5 weeks) trimesters of pregnancy. All interviews were
conducted in English or Spanish by bilingual, bicultural
interviewers using structured questionnaires.
Demographic data collected included maternal age, marital
status, educational attainment, country of birth, number of years
lived in the United States, language spoken in the home, family
income, and the number of people supported by that income.
Questionnaires also gathered information on behavioral charac-
teristics, including tobacco, alcohol, drug, and caffeine use, and
health information, including previous pregnancies and medical
conditions. Body mass index (BMI) was calculated using self-
reported pre-pregnancy weight and measured height. Data on
pregnancy complications and birth outcomes, including infant
birth weight, length, head circumference, and gestational age,
were abstracted from medical records by a registered nurse.
Pesticide Exposure Assessment
Spot urine samples were collected from mothers at the time of
each interview and stored at 280uC until shipment to the Centers
for Disease Control and Prevention (CDC) for analysis of OP
pesticide metabolites. Dialkyl phosphate (DAP) metabolites were
measured in urine samples using gas chromatography-tandem
mass spectrometry (GC-MS/MS) and quantified using isotope
dilution calibration [27]. Details of laboratory measurements and
quality control are described elsewhere [28].
Six DAP metabolites were quantified: three dimethyl phosphate
(DM) metabolites (dimethylphosphate, dimethyldithiophosphate,
dimethylthiophosphate) which are derived from pesticides such as
malathion, oxydemeton-methyl, and dimethoate, and three diethyl
phosphate (DE) metabolites (diethylphosphate, diethyldithiopho-
sphate, diethylthiophosphate) derived from pesticides such as
diazinon, chlorpyrifos, and disulfoton. Although not all OP
pesticides devolve to DAPs, approximately 80% of the OP
pesticides used in the Salinas Valley devolve to one or more of
these metabolites. DAP concentrations were converted to SI units
(nanomoles per liter) and summed to generate variables for total
DMs, total DEs, and total DAPs. All women had detectable levels
of DAP metabolites in their urine. For a small number of women
(n=8) levels of one metabolite could not be calculated due to
analytic interference. Because metabolites were highly correlated
within the DE or DM groups, regression was used to impute the
value of the missing metabolite based on the concentrations of the
Pesticide Exposure, PON1, and Birth Outcome
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determined using a commercially available diagnostic enzyme
method (Vitros CREA slides, Ortho Clinical Diagnostics, Raritan,
NJ).
PON1 Genotypes and Enzyme Activity
Maternal and fetal (umbilical cord) blood was collected at the
time of delivery and stored at 280uC. Analysis of PON1 genotype
and activity has been described previously [29]. Briefly, genotyp-
ing of the PON12108 and PON1192 SNPs was performed using
genomic DNA extracted from blood clots. For the coding SNP,
PON1192, we used the Taqman real-time PCR method with probes
custom-designed by Applied Biosystems, Inc. (Foster City, CA).
For the promoter SNP, PON12108, a two-part nested PCR strategy
was used: first, the region surrounding the SNP was pre-amplified
using non-allelic flanking primers, then the resulting amplicon was
diluted and served as the template for the subsequent Amplifluor
assay. Each plate of DNA incorporated randomly distributed
blank samples and duplicate DNA samples independently isolated
from the same subjects. We observed a high rate of concordance
(.99%) among duplicate DNA samples (4% of samples). All
discrepancies were resolved with additional genotyping.
Two substrate-specific PON1 enzyme activity assays (arylester-
ase and paraoxonase) were performed using spectrophotometric
methods as described by Huen et al. [20]. Arylesterase activity,
which measures the rate of hydrolysis of the substrate phenyl
acetate (in mmol/min/L of plasma), reflects quantity of PON1
enzyme [30,31]. In contrast, paroaxonase activity, which measures
the rate of hydrolysis of paraoxon, reflects a combination of the
catalytic efficiency and quantity of the PON1 enzyme. For quality
assurance, repeat samples and internal controls were included in
all assay runs. The average coefficient of variation (CV) for
internal control samples repeated throughout different assay runs
(inter-assay variability) was 7–9% and the average CV for repeated
samples ranged from 6–9% [20]. Both substrate-specific enzymatic
assays were performed in triplicate.
Statistical Analyses
Initial analyses used linear regression to examine the main
association of PON1 genotype and activity with length of gestation
and infant birth weight, length, and head circumference
independent of pesticide exposure. Maternal and child PON1
genotypes were examined categorically; for PON12108, the CC
genotype is the reference, and for PON1192, the RR genotype is the
reference. Arylesterase and paraoxonase activity in maternal and
umbilical cord blood were examined as continuous variables,
normalized by dividing by the standard deviation. Potential
confounders were selected a priori from the set of characteristics
known to be associated with birth outcome in this population.
Covariates were kept in the final models if they were also
associated with PON1 genotype or activity or if their exclusion
from the model changed the coefficient on the main effect by more
than 10%. Models of PON1 genotype included maternal pre-
pregnancy BMI and maternal weight gain during pregnancy as
covariates. Models of PON1 enzyme activity also included
maternal age and country of birth, as well as assay temperature,
since ambient temperature has been shown to affect hydrolysis
rates [20]. To explore PON1 status, we examined the association
of PON1 activity with birth outcome within each PON1192
genotype by stratifying by genotype and by testing for interaction
between activity and genotype using cross-product terms. As no
statistically significant interaction was found, analyses of PON1
activity on birth outcome controlled for PON1192 genotype as a
covariate but not as an effect modifier. Models of birth weight,
length and head circumference also controlled for gestational age
and gestational age
2 to examine associations independent of
gestational duration.
Subsequent analyses explored whether PON1 genotype or
activity was an effect modifier in the association of maternal DAP
metabolite concentrations and length of gestation or fetal growth.
Linear regression models were created for the association of total
urinary concentrations of DMs, DEs and DAPs with these birth
outcomes using the same methods and covariates as described in
our previously published study [12], but including either PON1
genotype (categorical variable) or activity (continuous variable)
and cross-product terms to test for interaction. For PON1
genotype, two cross-product terms were included in the model
(e.g. QR*DAP concentrations and RR*DAP concentrations), and
the overall statistical significance of both terms in the model was
determined using Wald tests. Similar cross-product terms were
generated using tertiles of PON1 activity. Statistical significance
for interaction was set at p-value,0.1. To further investigate effect
modification by PON1, we then stratified the linear regression
models by genotype or by tertiles of enzyme activity.
The variables for total concentrations of DMs, DEs and DAPs
were log-transformed to reduce the impact of outlier points. The
measurements at two time points during pregnancy were averaged
to create a summary measure of in utero OP pesticide exposure.
The analyses were conducted using DAP concentrations unad-
justed for creatinine. Subsequent sensitivity analyses included
creatinine as a covariate in the models.
Covariates included in the models were maternal age,
pregnancy weight gain, gestational age at first prenatal care visit
(in weeks), and gestational age at urine collection (in weeks) as
continuous variables and parity (0 or $1), infant sex, country of
birth (US or other), household income (#poverty or .poverty),
and maternal pre-pregnancy BMI (normal, overweight, or obese)
as categorical variables. Smoking, alcohol, and drug use were not
included in the final models because very few women reported use
and their inclusion did not alter the results.
Statistical analyses were performed using STATA/IC version
10.1 (StataCorp LP, College Station, TX).
Results
Characteristics of the study population are shown in Table 1.
Women were predominantly Spanish-speaking and born in
Mexico, with 41% of women working in agriculture during
pregnancy. More than 60% of families were living below the
federal poverty threshold and 89% of women had never completed
high school. The mean age was 25.5 years (SD=5.0). All women
had detectable levels of OP pesticide metabolites in their urine
during pregnancy. The geometric mean (GM) for the average
DAP concentrations during pregnancy was 146 nmol/L (95%
confidence interval (CI)=133, 160); of this, a larger proportion
was DM metabolites (GM=109 nmol/L; 95% CI=98, 120) than
DEs (GM=23 nmol/L; 95% CI=21, 25).
The allele frequencies of the PON1192 Q allele and the
PON12108 T allele were 50% and 46% in this population,
respectively, and did not differ between mothers and newborns.
The mean arylesterase and paraoxonase activity was 33.6 U/mL
(SD=16, range=4–145) and 256.6 U/L (SD=165, range=7–
1018), respectively, for infants and 136.6 U/mL (SD=44,
range=27–347) and 989.0 U/L (SD=616, range=75–3538) for
mothers.
Table 2 shows that individuals’ arylesterase and paraoxonase
activity varied by genotype. As expected, arylesterase activity (a
marker of enzyme quantity) was lowest among mothers and infants
Pesticide Exposure, PON1, and Birth Outcome
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combined measure of both quantity and enzyme efficiency) was
lower among mothers and infants with either the PON12108TT or
PON1192QQ genotype, suggesting that individuals with these
genotypes might be more susceptible to the adverse effects of
OP pesticide exposure. The lowest arylesterase and paraoxonase
levels were seen in mothers and infants who were homozygous for
both PON12108TT and PON1192QQ.
The independent association of infant PON1 genotype or
enzyme activity with birth outcome, without consideration of
pesticide metabolite levels, is shown in Table 3. Separate
regression models are shown for each genotype; the model for
arylesterase also includes PON1192 genotype to better capture
overall PON1 status. On average, infants with the susceptible
PON12108TT genotype were born earlier (b=20.5 weeks, 95% CI:
20.9, 0.0) and had smaller head circumferences (b=0.4 cm, 95%
CI: 20.7, 0.0), after controlling for confounders, than infants with
the PON12108CC genotype. Smaller head circumference was also
seen among infants with the PON12108CT genotype (b=20.3 cm,
95% CI: 20.6, 0.0) compared to those with PON12108CC.N o
associations were seen with PON1192; however, when the
PON12108 and PON1192 genotypes were combined, we observed
shorter gestation (b=21.1 weeks, 95% CI: 21.9, 20.4), birth
weight (b=2184.0 g, 95% CI: 2372.4, 4.4), and head circum-
ference (b=20.8 cm, 95% CI: 21.4, 20.2) among infants with
double homozygote PON12108TT/192QQ genotypes compared to
those with PON12108CC/192RR, with the magnitude of effect
considerably larger than for PON12108 genotype alone.
Similar results were seen with infant PON1 enzyme activity.
After controlling for PON1192 genotype, each standard deviation
increase in arylesterase activity was associated with 0.2 week (95%
CI: 0.1, 0.4) increase in gestational duration (Table 3). Paraox-
onase activity was similarly positively associated with gestational
age (not shown). Neither arylesterase nor paraoxonase activity was
associated with birth weight, length, or head circumference after
controlling for confounding variables.
The associations of PON1 with birth outcome were found only
with PON1 measured in infants, not in mothers. No associations
were found between any marker of PON1 genotype or activity
measured in maternal blood and gestational age or infant birth
weight, length, and head circumference (Table S1).
Results of the analysis of interaction between DAPs, PON1 and
birth outcome are shown in Table 4 along with the adjusted
association of DAPs and birth outcomes, stratified by either PON1
genotype or tertiles of arylesterase activity. The data stratified by
genotype are also shown graphically in Figure 1. Our previously
reported [12] associations of DAP concentrations in maternal
urine and birth outcome, not accounting for PON1, are shown in
grey on Figure 1. We previously reported a decrease in length of
gestation with prenatal DM metabolite levels and an unexplained
pattern of increased fetal growth, particularly for head circumfer-
ence, with DAP metabolite levels. In stratified analyses, maternal
DAP, DM and DE metabolite levels were all negatively associated
with length of gestation among infants with the susceptible
PON12108TT and PON1192QQ genotypes. The magnitude of the
association was consistently larger in the susceptible children than
in the total population, but did not reach statistical significance,
likely due to the reduced sample sizes. Each ten-fold increase in
maternal DAPs during pregnancy was associated with a 0.9 week
(95% CI: 22.0, 0.2) decrease in gestational age among
PON12108TT infants and a 1.0 week (95% CI: 22.0, 0.0) decrease
among PON1192QQ infants (Table 4 and Figure 1).
Figure 1 shows that the positive associations that we reported
between DAP concentrations and birth weight and head
circumference (in grey) persisted among infants with the non-
susceptible PON1 profiles. For example, among infants with the
PON1192RR genotype, each ten-fold increase in prenatal DEs was
associated with a 258.8 g (95% CI: 23.9, 493.6) increase in birth
weight and a 0.7 cm (95% CI: 0.0, 1.5) increase in head
circumference. Each 10-fold increase in DMs was associated with
Table 1. Demographic characteristics of CHAMACOS study
population, Salinas Valley, California, 2000–2001 (N=467).
Characteristic N (%)
Age (years)
18–24 225 (48.2)
25–29 144 (30.8)
30–34 69 (14.8)
$35 29 (6.2)
Parity
0 155 (33.2)
$1 312 (66.8)
Marital status
Single 94 (20.1)
Married/Living as Married 373 (79.9)
Language spoken at home
Spanish 412 (88.2)
English 28 (6.0)
Both Spanish and English 23 (4.9)
Other 4 (0.9)
Country of birth
Mexico 393 (84.2)
United States 64 (13.7)
Other 10 (2.1)
Family Income
Below poverty threshold 288 (61.7)
Above poverty threshold 179 (38.3)
Education
#6th grade 198 (42.4)
7–12th grade 170 (36.4)
High School Graduate 99 (21.2)
Pre-pregnancy BMI
Underweight 3 (0.7)
Normal 174 (38.2)
Overweight 183 (40.2)
Obese 95 (21.0)
Smoking during pregnancy
No 438 (93.8)
Yes 29 (6.2)
Work status during pregnancy
Worked in agriculture 188 (41.1)
Worked in other industry 104 (22.8)
Did not work 165 (36.1)
Infant sex
Boy 234 (50.1)
Girl 233 (49.9)
doi:10.1371/journal.pone.0023923.t001
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infants with high levels of arylesterase activity (Table 4). However,
among the susceptible infants with PON12108TT or PON1192QQ
genotype or low arylesterase activity, DAPs, DEs and DMs were
either not associated with fetal growth or were trending towards
decreased growth.
Results of tests for interaction between PON1 and DAPs are
shown in Table 4. Interaction p-values were derived from the full
regression models that included DAPs, genotype or tertiles of
activity, and cross-product terms, and represent the overall p-value
on both cross-product terms using the Wald test. Statistically
significant interaction was seen between DAPs (specifically DMs)
and PON1 genotype for head circumference (p-valueinteraction
terms=0.08 for PON12108 and 0.01 for PON1192) and birth weight
(p-valueinteraction terms=0.06 for PON12108). This interaction
appears to be driven by positive associations of DAPs with fetal
growth among those with non-susceptible genotypes. We did find
statistically significant interaction between DE metabolites and
PON12108 genotype for gestational age, supporting our finding
that prenatal DE exposure was associated with shorter length of
gestation only among the susceptible PON12108TT infants.
Although we observed similar patterns with gestational age for
PON1192 and for DAPs and DMs, the interaction terms for these
models were not statistically significant.
Discussion
This study found that infant, but not maternal, PON1 genotype
and activity were associated with birth outcome in a population of
pregnant women living in an agricultural community. Specifically,
Table 2. Distribution of PON1 genotype and enzyme activity in mothers and neonates, CHAMACOS Study, Salinas Valley, CA.
Arylesterase Activity (U/mL) Paraoxonase Activity (U/L)
N Mean (SD) Mean (SD)
Maternal genotype
PON12108 CC 106 149.83 (45.87)
a 1346.00 (694.66)
b
CT 171 136.22 (41.23)
a 938.95 (536.77)
b
TT 88 119.02 (40.24)
a 676.48 (444.31)
b
PON1192 RR 95 130.06 (38.70)
c 1659.00 (561.49)
d
QR 170 134.28 (39.39) 997.65 (341.46)
d
QQ 101 145.19 (53.38)
c 356.68 (269.28)
d
PON121086PON1192 CC/RR 44 35.44 (11.57) 338.17 (160.44)
CC/QR 41 40.65 (18.27) 299.52 (183.40)
CT/RR 30 35.55 (20.91) 328.17 (198.82)
CT/QR 73 34.38 (14.87) 276.03 (148.02)
CC/QQ 14 32.37 (10.25) 168.59 (138.74)
*
TT/RR 13 31.59 (11.78) 305.90 (155.16)
TT/QR 34 25.50 (12.03) 173.16 (117.64)
*
CT/QQ 41 30.54 (14.94) 178.25 (142.59)
*
TT/QQ 30 31.86 (24.56) 170.37 (108.54)
*
Infant genotype
PON12108 CC 94 41.78 (12.98)
e,f 343.00 (169.01)
g
CT 167 31.75 (13.76)
e 238.38 (145.43)
g
TT 57 26.52 (22.76)
f 168.53 (147.87)
g
PON1192 RR 76 36.60 (13.18) 405.68 (170.90)
h
QR 172 33.62 (18.06) 258.72 (117.67)
h
QQ 75 30.54 (15.04) 100.84 (96.13)
h
PON121086PON1192 CC/RR 34 43.47 (10.81) 481.06 (154.03)
CC/QR 47 40.61 (13.54) 296.87 (103.78)
*
CT/RR 33 30.39 (12.43)
* 347.72 (169.60)
*
CT/QR 92 32.15 (14.40)
* 261.78 (103.70)
*
CC/QQ 13 41.57 (16.38) 148.68 (107.73)
*
TT/RR 8 32.79 (13.20) 309.70 (116.79)
*
TT/QR 30 28.96 (28.94)
* 202.71 (149.12)
*
CT/QQ 42 31.92 (13.56)
* 101.22 (95.87)
*
TT/QQ 19 20.03 (11.10)
* 55.14 (50.21)
*
a,b,c,…Values with the same superscript are significantly different (p,0.05) in pairwise Bonferroni’s multiple comparison tests (PON12108 and PON1192 analyses).
*Values significantly different (p,0.05) from CC/RR individuals in pairwise Bonferroni’s multiple comparison tests (PON121086PON1192 analyses).
doi:10.1371/journal.pone.0023923.t002
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among infants who might be more susceptible to the effects of
exposure to OP pesticides, either because they had lower PON1
enzyme activity (measured as arylesterase or paraoxonase activity)
or because they were of a susceptible genotype (PON12108TT). This
suggests that low PON1 activity may be a factor contributing to
preterm birth or restricted fetal growth.
It is not clear whether this association of PON1 and birth
outcome is mediated through PON1’s role in OP pesticide
metabolism or oxidative stress. However, we did find evidence that
PON1 may be an effect modifier in the association of OP pesticide
exposure with birth outcome. Maternal DAP, DE, and DM
metabolite concentrations were associated with shorter duration of
gestation among infants with the susceptible PON12108TT and
PON1192QQ genotypes, although these findings were not statistically
significant within individual strata. Although the patterns of
decreased gestational age with DAP concentrations were similar
across both susceptible genotypes and for all types of DAP
metabolites, only the interaction between PON12108 genotype and
DE metabolite concentrations was statistically significant.
Our finding of an independent effect of PON1 genotype and
activity on birth outcome is consistent with the New York cohort
studied by Berkowitz et al. [25] and Wolff et al [11], the only other
study to examine PON12108 and arylesterase with birth outcome
(see Table 5). Like us, they found PON12108TT genotype to be
associated with smaller infant head circumference [25]. They also
found lower arylesterase activity to be associated with smaller head
size, while we found it to be associated with shorter gestation. A
difference in the studies is that, although both looked at maternal
and infant PON1, all of their associations were with maternal
PON1 genotype and activity while ours were with infant PON1.
Results with PON192 and paraoxonase activity are less consistent
(Table 5). Only one small study has examined paraoxonase activity
and birth weight; Roy et al.found the opposite of our study,
reporting that higher maternal paraoxonase activity was associated
with lower birth weight [32]. More studies have examined
PON1192 [11,33,34,35]. Consistent with our study, Ryckman et
al. [36] reported no association of the PON1192 maternal or child
genotype with preterm birth in two cohorts in Norway or
Tennessee. However, other studies found that mothers or infants
with the PON1192RR genotype were at increased risk of preterm
birth [33,34] shorter gestational age [35], or smaller birth size
[11]. These findings with PON1192 are the opposite of our
hypothesis that individuals with the PON1192RR would be at lower
risk of poor birth outcomes because of their improved efficiency at
detoxifying OP pesticides. However, individuals with the
PON1192RR genotype appear to be more susceptible to certain
oxidative stress pathways, another important mechanism for the
PON1 enzyme. Another possible explanation for the associations
of PON1192RR with poorer birth outcome found in these studies is
uncontrolled confounding by PON12108, since the two SNPs are in
linkage disequilibrium (D9=0.22, p-value 0.01) [29].
Our evidence for interaction between PON1 and OP exposure
on birth outcome is supported by three other studies [11,25,26].
None of these studies examined length of gestation, where we see
the strongest result in this study. All three previous studies report
statistically significant interaction between PON1 and markers of
pesticide exposure on fetal growth, although the details of this
Table 3. Association of infant PON1 genotype (N=436) and activity (N=324) with birth outcome, CHAMACOS Study, Salinas
Valley, CA.
Gestational Age (weeks) Birth Weight
a (g) Head Circumference
a (cm)
N b ( 95% CI ) b ( 95% CI ) b ( 95% CI )
Infant Genotype
PON12108 CC 131 ref ref ref
CT 225 0.1 (20.3, 0.4) 267.8 (156.2, 20.7) 20.3 (20.6, 0.0)*
TT 76 20.5 (20.9, 0.0)* 236.0 (2152.3, 80.3) 20.4 (20.7, 0.0)
PON1192 RR 106 ref ref ref
QR 222 0.1 (20.3, 0.4) 219.8 (2113.5, 73.9) 20.1 (20.4, 0.2)
QQ 108 20.3 (20.7, 0.2) 273.9 (2183.8, 36.0) 20.2 (20.6, 0.1)
PON121086PON1192
CCRR 49 ref ref ref
CCQR 57 20.1 (20.7, 0.5) 251.8 (2207.7, 104.2) 20.2 (20.7, 0.3)
CTRR 48 20.2 (20.9, 0.4) 2140.7 (2303.4, 21.9) 20.5 (21.1, 0.0)
CTQR 123 20.1 (20.5, 0.6) 2128.8 (2263.3, 5.7) 20.5 (21.0, 20.1)*
CCQQ 25 20.3 (21.1, 0.5) 2163.0 (2358.8, 32.8) 20.5 (21.1, 0.2)
TTRR 8 20.2 (21.4, 1.0) 247.7 (2350.4, 254.9) 20.8 (21.8, 0.1)
TTQR 39 20.2 (20.9, 0.4) 230.1 (2200.9, 140.6) 20.3 (20.8, 0.3)
CTQQ 53 0.0 (20.7, 0.6) 2105.6 (2263.9, 52.8) 20.4 (20.9, 0.1)
TTQQ 29 21.1 (21.9, 20.4)* 2184.0 (2372.4, 4.4) 20.8 (21.4, 20.2)*
Infant PON1 Status
Arylesterase
b 322 0.2 (0.1, 0.4)* 34.6 (210.9, 80.1) 0.1 (20.1, 0.2)
*p-value,0.05.
aModels adjusted for maternal BMI, maternal weight gain, gestational age, and (gestational age)
2.
bModels additionally adjusted for PON1192 genotype, maternal age, country of birth, and assay temperature. Change per 1 standard deviation increase in activity.
doi:10.1371/journal.pone.0023923.t003
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metabolite concentrations were negatively associated with birth
weight in the PON1192QQ mothers [11]. We find DE concentra-
tions to be negatively associated with length of gestation in the
PON1192QQ and PON12108TT infants. The New York studies also
found that, among mothers with low arylesterase levels, DM
Table 4. Adjusted association of log10 increase in DAPs and birth outcome, stratified by child PON1 genotype or tertiles of
arylesterase activity, CHAMACOS Study, Salinas Valley, CA.
Gestational Age
a Birth Weight
b Head Circumference
b
N b (95% CI)
Interaction
P-value b (95% CI)
Interaction
P-value b (95% CI)
Interaction
P-value
PON12108
Total DAPs
TT 76 20.8 (22.0, 0.2) 0.36 2131.3 (2393.3, 130.8) 0.06 { 0.1 (20.6, 0.9) 0.08 {
CT 225 20.3 (20.8, 0.3) 147.2 (18.5, 275.7)* 0.2 (20.2, 0.6)
CC 131 0.1 (20.7, 0.8) 22.1 (2182.0, 226.3) 0.6 (20.1, 1.3)
DEs
TT 76 21.0 (22.1, 0.1) 0.09 { 255.3 (2320.5, 209.8) 0.35 20.1 (20.8, 0.7) 0.19
CT 225 20.2 (20.8, 0.3) 120.8 (214.8, 256.4) 0.2 (20.2, 0.6)
CC 131 0.6 (20.2, 1.4) 45.4 (2174.6, 265.4) 0.6 (20.2, 1.4)
DMs
TT 76 20.6 (21.6, 0.4) 0.49 2135.2 (2373.8, 103.3) 0.05 { 0.2 (20.5, 0.8) 0.12
CT 225 20.3 (20.8, 0.2) 134.6 (14.9, 254.2)* 0.1 (20.3, 0.5)
CC 131 0.0 (20.7, 0.7) 46.8 (2132.5, 226.1) 0.5 (20.2, 1.1)
PON1192
Total DAPs
QQ 108 20.1 (22.0, 0.0) 0.21 260.2 (2266.3, 145.9) 0.20 20.3 (21.0, 0.4) 0.01 {
QR 222 20.2 (20.7, 0.3) 79.4 (248.5, 207.3) 0.2 (20.2, 0.6)
RR 106 0.2 (20.7, 1.1) 142.3 (2114.6, 399.3) 0.7 (20.1, 1.5)
DEs
QQ 108 21.0 (22.1, 0.2) 0.17 20.5 (2210.5, 251.5) 0.30 0.1 (20.7, 0.9) 0.27
QR 222 0.1 (20.4, 0.6) 67.2 (263.3, 197.5) 0.1 (20.3, 0.5)
RR 106 20.3 (21.2, 0.6) 258.8 (23.9, 493.6)* 0.7 (0.0, 1.5)
DMs
QQ 108 20.7 (21.7, 0.2) 0.25 280.6 (2269.2, 107.9) 0.16 20.4 (21.0, 0.2) 0.01 {
QR 222 20.3 (20.7, 0.1) 89.9 (227.8, 207.5) 0.2 (20.2, 0.5)
RR 106 0.3 (20.5, 1.2) 72.9 (2169.2, 315.0) 0.5 (20.3, 1.3)
Arylesterase Activity
Total DAPs
Low 108 0.3 (20.5, 1.2) 0.17 214.6 (2263.4, 234.3) 0.39 20.2 (21.0, 0.5) 0.32
Middle 108 20.4 (21.2, 0.4) 63.8 (2131.1, 258.7) 0.3 (20.3, 0.9)
High 108 20.2 (20.9, 0.5) 92.2 (2106.6, 291.1) 0.8 (0.1, 1.4)*
DEs
Low 108 20. (21.2, 0.4) 0.69 255.2 (2295.6, 185.2) 0.31 20.5 (21.2, 0.2) 0.48
Middle 108 20.7 (21.5, 0.1) 48.7 (2134.4, 231.8) 0.4 (20.2, 1.0)
High 108 0.5 (20.3, 1.2) 231.4 (19.1, 443.6) 0.7 (20.1, 1.4)
DMs
Low 108 0.5 (20.3, 1.2) 0.16 14.8 (2216.2, 245.7) 0.29 20.1 (20.8, 0.5) 0.36
Middle 108 20.4 (21.1, 0.4) 83.9 (294.8, 262.6) 0.1 (20.4, 0.7)
High 108 20.4 (21.0, 0.3) 60.2 (2120.2, 240.7) 0.7 (0.1, 1.3)*
aGestational age models adjusted for timing of urine collection, timing of entry into prenatal care, maternal age, parity, country of birth, and household income.
bModels of birth weight and head circumference adjusted for timing of urine collection, timing of entry into prenatal care, maternal age, parity, country of birth,
household income, prepregnancy BMI, maternal weight gain, infant sex, gestational age, and (gestational age)
2.
*p-value on stratified association ,0.05.
{p-value for interaction ,0.1.
doi:10.1371/journal.pone.0023923.t004
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and levels of a urinary metabolite of chlorpyrifos (a DE pesticide)
were negatively associated with head circumference [25]. Thus,
although there are differences in outcomes and in whether the
effect modification is due to infant or maternal PON1, these
studies all suggest that some individuals may be more susceptible
to negative health effects of resulting from exposure to OP
pesticides.
Examining interaction by PON1 expands on our earlier
findings of shorter duration of gestation with increasing in utero
DM levels. However, the only significant interaction that we
observed for gestational age was with DE concentrations, not
DMs. It is possible that the reason we did not observe an
association of gestational age with DE metabolites previously is
that it was masked by the role of PON1. Observing interaction
with DE concentrations is plausible since the known biologically
relevant action of PON1 is with two DE pesticides, chlorpyrifos
and diazinon. PON1 does not hydrolyze DM pesticides such as
malathion, oxydemeton-methyl, and dimethoate directly, but
may have an indirect effect on their toxicity; by detoxifying
chlorpyrifos oxon or diazoxon, PON1 prevents these OPs from
inhibiting the carboxylesterases that detoxify some of the DM
OPs. Thus, interaction of PON1 and DM metabolites is not
unexpected.
We previously reported borderline increases in birth weight and
head circumference associated with in utero DAP concentrations.
These findings are in contrast with other studies, notably Whyatt
et al., who that found OP pesticide levels in maternal blood were
Figure 1. Association of maternal urinary DAPs with birth outcome, stratified by infant PON1 genotype. Models of gestational age
controlling for timing of urine collection, timing of entry into prenatal care, maternal age, parity, country of birth, and poverty level. Models of birth
weight and head circumference control for timing of urine collection, timing of entry into prenatal care, maternal age, parity, infant sex, country of
birth, weight gain, BMI, poverty level, gestational age, and (gestational age)
2.
doi:10.1371/journal.pone.0023923.g001
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PON1 status served to magnify some of those positive associations,
such that in the non-susceptible groups (e.g. PON12108CC,
PON1192RR, and high arylesterase), increasing DAP concentrations
were associated with increased birth weight and head circumfer-
ence. We have no ready explanation for these findings, although it
is possible that, among the less susceptible groups, high DAP
concentrations in urine are actually an indication of high
metabolizers (i.e. those who detoxify and excrete OP pesticides
quickly), rather than high exposure.
The use of DAP metabolites to measure exposure has some
limitations. DAPs measure short term exposure to OP
pesticides. Although we took the average of two DAP
measurements, one in early and one in late pregnancy, they
may not reflect on-going exposure throughout gestation.
Additionally, DAP metabolites in urine may overestimate OP
pesticide exposure to the extent that they reflect exposure to
preformed DAPs in the environment as well as to the parent
OP compound [37]. Also, it is not known how DAP metabolite
levels and excretion patterns may differ by PON1 status, even
among individuals with similar exposures.
Despite its large sample size, this study also lacked power to
thoroughly examine interaction and conduct stratified analyses.
We examined only two main polymorphisms, PON1192 and
PON12108. Although we have recently shown that other PON1
polymorphisms are also associated with arylesterase and para-
oxonase activity in this cohort, most of them were in strong linkage
disequilibrium with the two examined in this study [38].
In summary, we found evidence for a main effect of infant
PON12108TTgenotypeandlowarylesteraseandparaoxonaseactivity
on shorter gestation and smaller head circumference. This finding
has important implications as a potential risk factor for preterm birth
and fetal growth restriction and adds to the growing body of
evidence that PON1genotype may affectchild development [39]. In
addition to itsroleindetoxificationand metabolismof OP pesticides,
PON1 appears to also play a strong role in metabolism of oxidized
lipids which was beyond the scope of this study.
This study also provides additional evidence that exposure to
OP pesticides may impact fetal growth and length of gestation,
particularly among individuals with increased susceptibility to OP
pesticides. Additional studies are needed to help resolve continuing
inconsistencies between the small number of existing studies.
Table 5. Comparison of studies of PON1 and birth outcome.
Study Population PON12108
1 PON1192
1 Arylesterase
2 Paraoxonase
2 Interaction with OP
pesticides?
Infant Mother Infant Mother Infant Mother Infant Mother
Harley, 2010 N=470
Rural California
TT:
Q GA,
Q Head
Null Null Null +GA Null +GA Null Among TT infants:
Q GA with DEs
Among CT or CC
infants
q Head, q BW with
DAPs, DMs
Among RR infants
q Head with DAPs,
DMs
Berkowitz, 2004 N=404
New York City
Null TT:
Q Head
– – Null +Head – – Among mothers with
low arylesterase:
Q Head with
Chlorpyrifos
Chen, 2008 N=185
China
––R R :
Increased
preterm
N u l l –––––
Lawlor, 2006 N=4286
UK
–––R R :
Increased
preterm
–––––
Min, 2006 N=276
Korea
–––R R :
Q BW
–––––
Moreno-Banda,
2009
N=264
Mexico
– – – Null – – – – Among QQ mothers:
Q LBW with work in
floriculture
Roy, 1994 N=91
Singapore
–––– – – – 2BW –
Ryckman, 2010 N=424
Norway
N=764
Tennessee
– – N u l l N u l l –––––
Wolff, 2007 N=404
New York City
– – Null RR:
Q BW
Q Head
Null +Head – – Among QQ mothers:
Q BW with DEs
Among mothers with
low arylesterase:
Q length with DMs
Abbreviations: BW=birth weight, LBW=low birth weight, GA=gestational age, Head=head circumference, – not examined.
1QGA indicates that genotype is associated with decreased GA; qGA indicates association with increased GA.
2+GA indicates that enzyme activity is positively associated with GA; 2GA indicates negative association with GA.
doi:10.1371/journal.pone.0023923.t005
Pesticide Exposure, PON1, and Birth Outcome
PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e23923Supporting Information
Table S1 Association of maternal PON1 genotype
(N=451) and activity (N=371) with birth outcome,
CHAMACOS Study, Salinas Valley, CA.
(DOC)
Author Contributions
Conceived and designed the experiments: KGH KH NTH AB BE.
Performed the experiments: KGH KH NTH AB DBB BE. Analyzed the
data: KGH KH RAS. Contributed reagents/materials/analysis tools: KH
NTH DBB. Wrote the paper: KGH KH NTH BE.
References
1. Keily T, Donaldson D, Grube A (2004) Pesticides Industry Sales and Usage:
2000 and 2001 Market Estimates. Washington, DC: US Environmental
Protection Agency.
2. Muto MA, Lobelle F, Jr., Bidanset JH, Wurpel JN (1992) Embryotoxicity and
neurotoxicity in rats associated with prenatal exposure to DURSBAN. Vet Hum
Toxicol 34: 498–501.
3. Breslin W, Liberacki A, Dittenber D, Quast J (1996) Evaluation of the
developmental and reproductive toxicity of chlorpyrifos in the rat. Fundamental
and Applied Toxicology 29: 119–130.
4. Chanda SM, Harp P, Liu J, Pope CN (1995) Comparative developmental and
maternal neurotoxicity following acute gestational exposure to chlorpyrifos in
rats. J Toxicol Environ Health 44: 189–202.
5. Maurissen JP, Hoberman AM, Garman RH, Hanley TR, Jr. (2000) Lack of
selective developmental neurotoxicity in rat pups from dams treated by gavage
with chlorpyrifos. Toxicol Sci 57: 250–263.
6. Spyker JM, Avery DL (1977) Neurobehavioral effects of prenatal exposure to the
organophosphate Diazinon in mice. J Toxicol Environ Health 3: 989–1002.
7. Srivastava MK, Raizada RB (1996) Development effect of technical dimethoate
in rats: maternal and fetal toxicity evaluation. Indian J Exp Biol 34: 329–333.
8. Qiao D, Seidler FJ, Padilla S, Slotkin TA (2002) Developmental neurotoxicity of
chlorpyrifos: what is the vulnerable period? Environ Health Perspect 110:
1097–1103.
9. Whyatt RM, Rauh V, Barr DB, Camann DE, Andrews HF, et al. (2004)
Prenatal insecticide exposures and birth weight and length among an urban
minority cohort. Environ Health Perspect 112: 1125–1132.
10. Barr DB, Ananth CV, Yan X, Lashley S, Smulian JC, et al. (2010) Pesticide
concentrations in maternal and umbilical cord sera and their relation to birth
outcomes in a population of pregnant women and newborns in New Jersey. Sci
Total Environ 408: 790–795.
11. Wolff MS, Engel S, Berkowitz G, Teitelbaum S, Siskind J, et al. (2007) Prenatal
pesticide and PCB exposures and birth outcomes. Pediatr Res 61: 243–250.
12. Eskenazi B, Harley K, Bradman A, Weltzien E, Jewell NP, et al. (2004)
Association of in utero organophosphate pesticide exposure and fetal growth and
length of gestation in an agricultural population. Environ Health Perspect 112:
1116–1124.
13. Costa LG, Richter RJ, Li WF, Cole T, Guizzetti M, et al. (2003) Paraoxonase
(PON 1) as a biomarker of susceptibility for organophosphate toxicity.
Biomarkers 8: 1–12.
14. Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, et al. (2010)
Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact
187: 355–361.
15. Aviram M, Rosenblat M (2004) Paraoxonases 1, 2, and 3, oxidative stress, and
macrophage foam cell formation during atherosclerosis development. Free
Radic Biol Med 37: 1304–1316.
16. Li HL, Liu DP, Liang CC (2003) Paraoxonase gene polymorphisms, oxidative
stress, and diseases. J Mol Med 81: 766–779.
17. Stoltz DA, Ozer EA, Taft PJ, Barry M, Liu L, et al. (2008) Drosophila are
protected from Pseudomonas aeruginosa lethality by transgenic expression of
paraoxonase-1. J Clin Invest 118: 3123–3131.
18. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, et al. (2000) Catalytic
efficiency determines the in-vivo efficacy of PON1 for detoxifying organophos-
phorus compounds. Pharmacogenetics 10: 767–779.
19. Richter R, Jampsa R, Jarvik G, Costa LG, Furlong CE (2004) Determination of
Paraoxonase 1 (PON1) Status and Genotypes at Specific Polymorphic Sites. In:
Maines M, ed. Current Protocols in Toxicology. HobokenNJ: Wiley and Sons.
pp 4.12.11–14.12.19.
20. Huen K, Richter R, Furlong C, Eskenazi B, Holland N (2009) Validation of
PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta 402:
67–74.
21. Furlong CE, Holland N, Richter RJ, Bradman A, Ho A, et al. (2006) PON1
status of farmworker mothers and children as a predictor of organophosphate
sensitivity. Pharmacogenet Genomics 16: 183–190.
22. Deakin SP, James RW (2004) Genetic and environmental factors modulating
serum concentrations and activities of the antioxidant enzyme paraoxonase-1.
Clin Sci (Lond) 107: 435–447.
23. Costa LG, Cole TB, Jarvik GP, Furlong CE (2003) Functional genomic of the
paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovas-
cular disease, and drug metabolism. Annu Rev Med 54: 371–392.
24. Deakin S, Leviev I, Brulhart-Meynet MC, James RW (2003) Paraoxonase-1
promoter haplotypes and serum paraoxonase: a predominant role for
polymorphic position - 107, implicating the Sp1 transcription factor.
Biochem J 372: 643–649.
25. Berkowitz GS, Wetmur JG, Birman-Deych E, Obel J, Lapinski RH, et al. (2004)
In utero pesticide exposure, maternal paraoxonase activity, and head
circumference. Environ Health Perspect 112: 388–391.
26. Moreno-Banda G, Blanco-Munoz J, Lacasana M, Rothenberg SJ, Aguilar-
Garduno C, et al. (2009) Maternal exposure to floricultural work during
pregnancy, PON1 Q192R polymorphisms and the risk of low birth weight. Sci
Total Environ 407: 5478–5485.
27. Bravo R, Driskell WJ, Whitehead RD, Jr., Needham LL, Barr DB (2002)
Quantitation of dialkyl phosphate metabolites of organophosphate pesticides in
human urine using GC-MS-MS with isotopic internal standards. J Anal Toxicol
26: 245–252.
28. Bradman A, Eskenazi B, Barr D, Bravo R, Castorina R, et al. (2005)
Organophosphate urinary metabolite levels during pregnancy and after delivery
in women living in an agricultural community. Environ Health Perspect 113:
1802–1807.
29. Holland N, Furlong C, Bastaki M, Richter R, Bradman A, et al. (2006)
Paraoxonase polymorphisms, haplotypes, and enzyme activity in latino mothers
and newborns. Environ Health Perspect 114: 985–991.
30. Connelly PW, Maguire GF, Picardo CM, Teiber JF, Draganov D (2008)
Development of an immunoblot assay with infrared fluorescence to quantify
paraoxonase 1 in serum and plasma. J Lipid Res 49: 245–250.
31. Kujiraoka T, Oka T, Ishihara M, Egashira T, Fujioka T, et al. (2000) A
sandwich enzyme-linked immunosorbent assay for human serum paraoxonase
concentration. J Lipid Res 41: 1358–1363.
32. Roy AC, Loke DF, Saha N, Viegas OA, Tay JS, et al. (1994) Interrelationships
of serum paraoxonase, serum lipids and apolipoproteins in normal pregnancy. A
longitudinal study. Gynecol Obstet Invest 38: 10–13.
33. Chen D, Hu Y, Chen C, Yang F, Fang Z, et al. (2004) Polymorphisms of the
paraoxonase gene and risk of preterm delivery. Epidemiology 15: 466–470.
34. Lawlor DA, Gaunt TR, Hinks LJ, Davey Smith G, Timpson N, et al. (2006) The
association of the PON1 Q192R polymorphism with complications and
outcomes of pregnancy: findings from the British Women’s Heart and Health
cohort study. Paediatr Perinat Epidemiol 20: 244–250.
35. Min J, Park H, Park B, Kim YJ, Park J, et al. (2006) Paraoxonase gene
polymorphism and vitamin levels during pregnancy: Relationship with maternal
oxidative stress and neonatal birthweights. Reprod Toxicol 22: 418–424.
36. Ryckman KK, Morken NH, White MJ, Velez DR, Menon R, et al. (2010)
Maternal and fetal genetic associations of PTGER3 and PON1 with preterm
birth. PLoS One 5: e9040.
37. Weerasekera G, Smith K, Quiro ´s-Alcala ´ L, Fernandez C, Bradman A, et al.
(2009) A mass spectrometry-based method to measure dialkylphosphate
degradation products of organophosphorous insecticides in dust and orange
juice. Journal of Environmental Monitoring 11: 1345–1351.
38. Huen K, Barcellos L, Beckman K, Rose S, Eskenazi B, et al. (In Press.) Effects of
PON Polymorphisms and Haplotypes on Molecular Phenotype in Mexican-
American Mothers and Children. Environmental and Molecular Mutagenesis.
39. Eskenazi B, Huen K, Marks A, Harley K, Bradman A, et al. (2010) PON1 and
Neurodevelopment in Children from the CHAMACOS Study Exposed to
Organophosphate Pesticides in Utero. Environ Health Perspect.
Pesticide Exposure, PON1, and Birth Outcome
PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e23923